Merck & Co., Inc. (MRK) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers Merck & Co., Inc.'s unaudited financial results for the quarterly period ended June 30, 2025. Merck operates two primary segments: Pharmaceutical (human health) and Animal Health. The reporting period reflects significant strategic shifts, including a major restructuring initiative, a pause in Gardasil shipments to China, and continued growth in oncology and cardiovascular franchises.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Sales (Revenue) | $15.81 billion | $16.11 billion | $31.34 billion | $31.89 billion |
| Net Income (Attributable to Merck) | $4.43 billion | $5.46 billion | $9.51 billion | $10.22 billion |
| Diluted EPS | $1.76 | $2.14 | $3.77 | $4.02 |
| Operating Cash Flow (YTD) | $5.79 billion | $8.73 billion | - | - |
| Free Cash Flow (YTD) | $3.70 billion | $7.08 billion | - | - |
| Total Debt | $35.40 billion | $37.11 billion | - | - |
| Cash & Investments | $9.40 billion | $14.15 billion | - | - |
| Gross Margin | 77.5% | 76.8% | 77.7% | 77.2% |
Material Changes vs. Prior Period
- Revenue Decline: Worldwide sales decreased 2% year-over-year in both Q2 and YTD 2025. This was driven by a 55% drop in Gardasil/Gardasil 9 sales (due to paused shipments to China and lower demand in Japan) and the loss of Simponi/Remicade sales following the transfer of marketing rights to Johnson & Johnson in late 2024.
- Profitability Pressure: Net income declined 19% in Q2 and 7% YTD. This was primarily due to lower sales volumes and a significant increase in restructuring costs ($560 million in Q2 2025 vs. $80 million in Q2 2024).
- Restructuring Initiative: In July 2025, Merck announced a new restructuring program with estimated cumulative costs of $3.0 billion, aiming for $1.7 billion in annual cost savings by 2027. Q2 2025 included $649 million in costs related to this new program and the ongoing 2024 program.
- Key Growth Drivers: Despite the overall decline, Keytruda sales grew 9% in Q2 and 7% YTD. Winrevair (cardiovascular) sales grew significantly following its 2024 launch. Animal Health sales increased 11% in Q2.
- China Exposure: Gardasil sales in China dropped precipitously due to elevated channel inventory. Merck paused shipments in February 2025 and expects no further shipments through the end of 2025.
Guidance, Outlook, and Risks
- Outlook: Management expects the Gardasil sales decline to persist through 2025. The company anticipates significant sales declines for Januvia/Janumet in 2026 due to patent expirations and the Inflation Reduction Act (IRA) price negotiations.
- Regulatory & Pricing Risks:
- IRA Impact: Januvia is subject to government price setting effective Jan 1, 2026. Janumet and Janumet XR are subject to price setting effective Jan 1, 2027. Keytruda is now eligible for selection in 2027 (effective 2029) following the enactment of the "One Big Beautiful Bill Act" (OBBBA).
- Tariffs: The company anticipates approximately $200 million in additional expenses in 2025 due to U.S. tariffs on foreign imports.
- Legal Contingencies:
- IRS Audit: Merck received Notices of Proposed Adjustment (NOPAs) regarding the 2017/2018 transition tax, proposing an increase of approximately $1.3 billion plus $260 million in penalties. Merck plans to vigorously contest this.
- Product Liability: Approximately 575 cases pending regarding Dr. Scholl's foot powder and 125 cases regarding Gardasil. Merck recently won summary judgment in 16 Gardasil bellwether cases, though plaintiffs have appealed.
- Business Development: Merck agreed to acquire Verona Pharma for approximately $10 billion (closing expected Q4 2025) to add Ohtuvayre (COPD treatment). A $200 million upfront payment for a Lipoprotein(a) inhibitor license with Hengrui Pharma was recorded in Q2 R&D expenses.
Investor Verification Checklist
- China Sales Trajectory: Verify the duration of the Gardasil shipment pause and the potential for inventory normalization in 2026.
- Restructuring Execution: Monitor the realization of the projected $1.7 billion in annual cost savings from the 2025 restructuring program.
- IRS Dispute Resolution: Track the status of the $1.56 billion (tax + penalties) IRS proposed adjustment and the likelihood of a material charge.
- Keytruda Pipeline: Assess the impact of the withdrawn BLA for patritumab deruxtecan (HER3-DXd) and the progress of subcutaneous pembrolizumab (MK-3475A) with a PDUFA date of September 2025.
- Januvia/Janumet Decline: Evaluate the magnitude of sales erosion expected in 2026 due to the combination of patent cliffs and IRA price negotiations.